Brief: Astellas Pharma Inc - Update On Marketing Authorization Application For Avacincaptad Pegol (Acp) In The European Union
27/10/2024 23:06
Oct 28 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC - UPDATE ON MARKETING AUTHORIZATION
APPLICATION FOR AVACINCAPTAD PEGOL (ACP) IN THE EUROPEAN UNION
* ASTELLAS PHARMA INC - ANNOUNCED DECISION TO WITHDRAW ITS
MARKETING AUTHORIZATION APPLICATION FROM THE EUROPEAN MEDICINES
AGENCY FOR AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION
Source text: ID:nTSva7ae6d
Further company coverage: 4503.T
(Reporting by Satoshi Sugiyama)
((Satoshi.Sugiyama@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn